DOR BioPharma Submits European Marketing Application for orBecR to Treat GI Graft-Versus-Host Disease SYS-CON Media
DOR BioPharma, Inc. (OTCBB: DORB) ('DOR' or the'Company') announced today that it has submitted a Marketing AuthorizationApplication ('MAA') to the European Medicines Evaluation Agency ('EMEA') tomarket orBec® (oral beclomethasone dipropionate) for the treatment ofgastrointestinal Graft-versus-Host disease ('GI GVHD'), the most commonlife-threatening complication of allogeneic hematopoietic stem
Pipex Therapeutics' COPREXA Pivotal Clinical Trial Results Presented At NIH-Sponsored Wilson's Disease Association PrimeZone via Yahoo! Finance
Pipex Therapeutics, Inc. , a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that the pivotal clinical trial results of its lead drug candidate, COPREXA a new treatment being developed for initially-presenting neurologic Wilson's disease, were presented at the Wilson's Disease Association
pSivida in Negotiation With Biotech Fund for A$33.7M US$26M for Development Funding and Equity Investment RedNova
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that it is negotiating a non-binding Memorandum of Understanding (MOU) with an investment fund specializing in the biotech sector (the Investor).
DOR BioPharma Submits European Marketing Application for orBecR to Treat GI Graft-Versus-Host Disease Market Wire via Yahoo! Finance
DOR BioPharma, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Evaluation Agency to market orBec® for the treatment of gastrointestinal Graft-versus-Host disease, the most common life-threatening complication of allogeneic hematopoietic stem cell plantation in cancer patients. The MAA will be reviewed under the centralized licensing
CuraGen and TopoTarget Announce Updated PXD101 Phase Ib Results Presented at the EORTC-NCI-AACR Symposium FinanzNachrichten
BRANFORD, Conn., Nov. 10 /PRNewswire-FirstCall/ -- CuraGen Corporation ( Nachrichten ) and TopoTarget ( Nachrichten ) A/S (Copenhagen Stock Exchange: TOPO) today announced updated results from a Phase Ib trial of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors, along with three additional posters
CuraGen and TopoTarget Announce Updated PXD101 Phase Ib Results Presented at the EORTC-NCI-AACR Symposium PR Newswire via Yahoo! Finance
CuraGen Corporation and TopoTarget A/S today announced updated results from a Phase Ib trial of PXD101, a small molecule histone deacetylase inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors, along with three additional posters on PXD101, were presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held
Good news for Snider; improvement for Cox The Alaska Star
This is the final installment of a three-part series updating the status of area residents who have battled dramatic illnesses or injuries previously covered in The Star.
NoxafilR Posaconazole Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections RedNova
KENILWORTH, N.J., Nov. 9 /PRNewswire-FirstCall
New Research Identifies Unique Estrogen Augmented Mechanism For Enhanced Efficacy Of XYOTAXTM In Women Medical News Today
At the 18th Annual meeting of the European Organization for Research and Treatment of Cancers, National Cancer Institute and American Association for Cancer Research (EORTC-NCI-AACR), Cell Therapeutics, Inc. [click link for full article]
BioSphere Medical Receives FDA Approval For QuadraSphereTM Microspheres Business Wire via Yahoo! Finance
ROCKLAND, Mass.----BioSphere Medical, Inc. , a medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations, today announced that the U.S.

UCTV--University of California Television
Liver Disease Update: HIV and HCV Coinfection (#7194; 50 min.) American Liver Foundation offers an update on liver disease. Tarek Hassanein, M.D., from the
Update: Fatal and Severe Liver Injuries Associated With Rifampin
Update: Fatal and Severe Liver Injuries Associated With Rifampin and Patient 2 had no risks for chronic liver disease and had neither a liver biopsy nor
AASLDPRACTICEGUIDELINE Chronic Hepatitis B: Update of Recommendations
Chronic Hepatitis B: Update of Recommendations. Anna S.F. Lok. 1. and Brian J. McMahon and compensated liver disease should be observed for 3 to
HepNet - UPDATE ON LIVER DISEASE & HEPATITIS
The following abstracts are from presentations made at the Update On Liver Disease & Hepatitis Conference in Florida on June 4 to 8, 1997.
Clinical pharmacokinetic and pharmacodynamic considerations in
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. DJ MORGAN, AJ MCLEAN Clinical pharmacokinetics 29:55,

HepNet - UPDATE ON LIVER DISEASE & HEPATITIS
The following abstracts are from presentations made at the Update On Liver Disease & Hepatitis Conference in Florida on June 4 to 8, 1997.
Clinical pharmacokinetic and pharmacodynamic considerations in
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. DJ MORGAN, AJ MCLEAN Clinical pharmacokinetics 29:55,
Update on nonalcoholic fatty liver disease
Update on nonalcoholic fatty liver disease. Arthur J MCCULLOUGH Journal of clinical gastroenterology 34:33, 255-262, Lippincott Williams & Wilkins, 2001.
AASLDPRACTICEGUIDELINE Chronic Hepatitis B: Update of Recommendations
Chronic Hepatitis B: Update of Recommendations. Anna S.F. Lok. 1. and Brian J. McMahon and compensated liver disease should be observed for 3 to
Alcohol and the Liver Research Update
Alcohol and the Liver: Research Update--A Commentary by NIAAA Director Enoch Gordis, M.D Serious alcoholic liver disease (ALD) is a major public health
liverdisease.com--liver disease,hepatitis & hepatitis C
We are pleased to announce the publication of the long-awaited update to the bestselling book, "Dr. Melissa Palmer's Guide to HEPATITIS & LIVER DISEASE".
Alcohol and the Liver - Alcohol Alert No. 42-1998
Alcohol and the Liver: Research Update. Alcohol-induced liver disease (ALD) is a major cause of illness and death in the United States.
IngentaConnect Effects of Liver Disease on Pharmacokinetics: An Update
Effects of Liver Disease on Pharmacokinetics: An Update. Author: Rodighiero V.1. Source: Clinical Pharmacokinetics, Volume 37, Number 5, November 1999, pp.